StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Aimovig (erenumab-aooe by Quarter

Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%)

QuarterlyAnnual

Amgen Aimovig (erenumab-aooe: -32.0% in Q4 2023, down 59.0 pts from a year earlier. That is the lowest of the 17 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2023
-32.0%
Period ended Dec 31, 2023
Change on a year earlier
-59.0 pts
27.0% in Q4 2022
History
17 quarters
Since Q4 2019
Sources
17
Documents cited below

Where the Q4 2023 figure comes from

“|| Aimovig ® | 73 | 5 | 78 | 114 | (32%)”

Source: Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗

Reported in Form 8-K Product Sales Detail by Product and Geographic Region.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%)Year on yearSource
Q4 2023Dec 31, 2023-32.0%-59.0 ptsForm 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 2023-12.0%-47.0 ptsForm 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 2023-11.0%-23.0 ptsForm 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 2023-32.0%-85.0 ptsForm 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 202227.0%+40.0 ptsForm 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 202235.0%+60.0 ptsForm 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗
Q2 2022Jun 30, 202212.0%+28.0 ptsForm 8-K (amgn-2022630earningsrelease.htm, filed 2022-08-04) ↗
Q1 2022Mar 31, 202253.0%+60.0 ptsForm 8-K (amgenq12022earningsrelease.htm, filed 2022-04-27) ↗
Q4 2021Dec 31, 2021-13.0%-19.0 ptsForm 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗
Q3 2021Sep 30, 2021-25.0%-84.0 ptsForm 8-K (amgn-2021930xq3ex991.htm, filed 2021-11-02) ↗
Q2 2021Jun 30, 2021-16.0%-34.0 ptsForm 8-K (amgn-2021630xq2ex991.htm, filed 2021-08-03) ↗
Q1 2021Mar 31, 2021-7.0%-27.0 ptsForm 8-K (amgn-2021331xq1ex991.htm, filed 2021-04-27) ↗
Q4 2020Dec 31, 20206.0%+3.0 ptsForm 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗
Q3 2020Sep 30, 202059.0%–Form 8-K (amgn-2020930xq3ex991.htm, filed 2020-10-28) ↗
Q2 2020Jun 30, 202018.0%–Form 8-K (amgn-2020630xq1ex991.htm, filed 2020-07-28) ↗
Q1 2020Mar 31, 202020.0%–Form 8-K (amgn-2020331xq1ex991.htm, filed 2020-04-30) ↗

Cite this data

StockData. (2026). Amgen Aimovig (erenumab-aooe (%), quarterly Q4 2019–Q4 2023 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-aimovig-yoy

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.